XBIO
Price:
$4.105
Market Cap:
$6.33M
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Se...[Read more]
Industry
Biotechnology
IPO Date
2016-06-30
Stock Exchange
NASDAQ
Ticker
XBIO
According to Xenetic Biosciences, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -509075.00. This represents a change of -66.54% compared to the average of -1521402.53 of the last 4 quarters.
The mean historical Enterprise Value of Xenetic Biosciences, Inc. over the last ten years is 2.94M. The current -509075.00 Enterprise Value has changed -1831.71% with respect to the historical average. Over the past ten years (40 quarters), XBIO's Enterprise Value was at its highest in in the December 2016 quarter at 362.26M. The Enterprise Value was at its lowest in in the December 2022 quarter at -8774786.85.
Average
2.94M
Median
-765630.56
Minimum
-9043302.45
Maximum
27.90M
Discovering the peaks and valleys of Xenetic Biosciences, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 5.74%
Maximum Annual Enterprise Value = 27.90M
Minimum Annual Increase = -414.62%
Minimum Annual Enterprise Value = -9043302.45
Year | Enterprise Value | Change |
---|---|---|
2023 | -3710721.50 | -58.97% |
2022 | -9043302.45 | 82.45% |
2021 | -4956561.00 | -414.62% |
2020 | 1.58M | -125.25% |
2019 | -6240335.60 | -143.62% |
2018 | 14.30M | 28.91% |
2017 | 11.10M | -60.23% |
2016 | 27.90M | 5.74% |
2015 | 478.19K | -123.80% |
2014 | -2009450.00 | -51.35% |
The current Enterprise Value of Xenetic Biosciences, Inc. (XBIO) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-5903528.32
5-year avg
-4475098.47
10-year avg
2.94M
Xenetic Biosciences, Inc.’s Enterprise Value is less than TransCode Therapeutics, Inc. (4.92M), less than Landos Biopharma, Inc. (42.62M), greater than NexImmune, Inc. (-1935978.00), less than Oncorus, Inc. (42.71M), less than ZyVersa Therapeutics, Inc. (2.53M), less than Immix Biopharma, Inc. (30.53M), greater than Phio Pharmaceuticals Corp. (-2783607.00), less than 180 Life Sciences Corp. (4.73M), greater than Navidea Biopharmaceuticals, Inc. (-2504975.00), greater than Revelation Biosciences, Inc. (-3300245.00), less than YS Biopharma Co., Ltd. (1.72B), less than GeoVax Labs, Inc. (19.24M), less than NovaBay Pharmaceuticals, Inc. (3.81M), greater than Sonnet BioTherapeutics Holdings, Inc. (-907921.00), greater than Palisade Bio, Inc. (-4438971.00), less than Bright Minds Biosciences Inc. (337.02M), less than Virax Biolabs Group Limited (5.36M), less than Tonix Pharmaceuticals Holding Corp. (13.15M), greater than Zura Bio Limited (-9969663.00), less than Altamira Therapeutics Ltd. (909.70K), less than Enveric Biosciences, Inc. (202.96K),
Company | Enterprise Value | Market cap |
---|---|---|
4.92M | $6.64M | |
42.62M | $71.68M | |
-1935978.00 | $488.13K | |
42.71M | $0 | |
2.53M | $2.65M | |
30.53M | $49.14M | |
-2783607.00 | $2.61M | |
4.73M | $4.45M | |
-2504975.00 | $100.08K | |
-3300245.00 | $3.24M | |
1.72B | $192.09M | |
19.24M | $27.84M | |
3.81M | $3.33M | |
-907921.00 | $2.50M | |
-4438971.00 | $3.24M | |
337.02M | $245.49M | |
5.36M | $8.73M | |
13.15M | $35.51M | |
-9969663.00 | $178.25M | |
909.70K | $1.60M | |
202.96K | $3.31M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Xenetic Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Xenetic Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Xenetic Biosciences, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Xenetic Biosciences, Inc. (XBIO)?
What is the 3-year average Enterprise Value for Xenetic Biosciences, Inc. (XBIO)?
What is the 5-year average Enterprise Value for Xenetic Biosciences, Inc. (XBIO)?
How does the current Enterprise Value for Xenetic Biosciences, Inc. (XBIO) compare to its historical average?